Understanding the Market | JOINN rises over 3%, recently assisting YK012, an innovative bispecific antibody, in obtaining FDA IND approval in the United States

JOINN rose over 3%, as of the time of publication, up 3.6%, reported at HKD 19.87, with a trading volume of HKD 25.7499 million. In terms of news, according to JOINN's official WeChat account, recently, Yikesi Technology's independently developed targeted CD19/CD3 innovative bispecific antibody YK012 officially received clinical trial approval (IND) from the U.S. Food and Drug Administration (FDA) for the treatment of primary membranous nephropathy (pMN). This is the world's first T cell engager (TCE) bispecific antibody drug approved for clinical use for this indication, marking a synchronized breakthrough in original Chinese bispecific antibody technology in the field of autoimmune diseases. JOINN, as Yikesi Technology's non-clinical CRO partner, fully participated in the pharmacokinetic services, toxicology tests, and other non-clinical trial processes of the YK012 project. It is reported that the development of YK012 relies on Yikesi Technology's "Beijing headquarters + wholly-owned subsidiary Excyte LLC in the U.S." dual-center layout. Following the FDA IND approval, the company will gradually initiate international multicenter clinical research, complementing the multicenter trials already underway in China (led by Professor Zhao Minghui from Peking University First Hospital) to accelerate the global R&D process